And it would be a concession that prior to the label change they had been infringing and owe treble damages...

If a BP was sanguine about the air cover in Europe until 2039, it should be easy to envision re-establishing the $1bn footprint of Lovaza, and $1bn in sales (by say 2037) with a 13-year ramp should be worth at least $2-$3bn on a PV basis -- maybe more.

That would be $5 to $7.50 per share.

Investors are likely to view claims of patent-driven exclusivity skeptically after the Du debacle. Of course, the Euro patents should be way stronger, being based on REDUCE-IT, but short-term stock price impact won't be the result of closely examining that.

If your base case is $8 to $15, then I'm the pessimist here.

$5 to $7. $7 being miraculous.

I think this is a buying opportunity but I wouldn’t be in any hurry to— why pay 97 cents when you can pay 80 cents?

I want bankers running this business

All the real "pharma" is out of this company. A single underestablished drug, no real pipeline, and a world to get sales in.

A good sales and M&A leadership with no pharma experience at all would be better than what we had before Denner took over.

This rally is happening on modest volume, very curious

I'm looking forward to the latest MRM analysis

I love this opinion

It isn't realistic, but I love it

Yes -- several months ago MRM requested that I change my handle to change the company's karma.

So far it has been reasonably successful.

Yeah, spot on. FFS is what he is. It took me awhile to accept the creative historian in him, but it's well worth it. I'm glad he's here!

They do medicine for fish, not medicine made out of fish.

Leave FFS alone. He provides great entertainment to this board and gives us something to talk about.

The alternative is listening to blowhards complain.

That and the Sunday crossword puzzle — traditions I really miss

No it isn't, and enjoying reading someone you disagree with is a lost art in this grim age.

An oxymoron is a direct contradiction in a term. Like Military Intelligence or Plastic Silverware.

You just note your posts that fit with what happened, and then omit the ones where you were wrong.

But you have the best charts of anyone, so I still like to read your posts.

It's like reading the funnies in the Sunday paper.

Don't block him. He's funny as hell and has literally the best charts and pictures in all of chat boarding.

No stones, no clown, no mocking

Just watching you do what you do

Where is FFS by the way?

Oh I know... waiting for a pullback so he can recreate a past where he was right.

I mean, come on -- $1bn in global sales, sell it for 2x sales, that's $2bn = $5 per share

Are we arguing we can get higher peak sales? And even if we can -- how long is the runout on a single drug?

Can somebody show me the financials that go with $15 to $20 per share.

I choke the numbers to the ground, screaming and bleeding, and get past $5.

I thought FFS said the stock would tank.

Listen, this is silly

Whatever actually happens, he'll say that's what he predicted.

We've been through this Three Stooges routine so many times it's amazing there is still appetite for it.

(I have to confess I still actually have appetite for it... 🤪)

For Big Pharma, anything under $10 billion is not really a "big acquisition".

This is a penny stock and so you have to expect it's going to get ridden up and down on news -- and in the absence of news, the penny stock momo money goes elsewhere.

When we get back above $5, you can expect more normal trading patterns.

Hi Dusty -- there's a wild range of expectations here, created in part by history. A lot of us hold stock that was once as high as $26.

I think if an analyst from Mars landed here and did the math on this company, "it" would look at possible revenue projections and conclude they might peak sales at around $2bn (best case) -- that would translate to net income of around $500mm or so, and after buybacks you might get down to 300mm shares (best case).

So with a P/E of 8 (no, this company doesn't deserve biotech multiples, it's a one-drug company with no pipeline) -- you could conceivably get this thing above $10.

I think $3 to $5 is more realistic -- I would kill for $5.

Actually I think an eye doctor is an Ophthalmologist... an Optometrist is just someone who fits you for glasses...

MRM.....

Thank God FFS made a bearish post!

That's jet fuel for a rally!

This is the standard runup into JPM, which assumes something substantial will be revealed at the meeting.
If it isn't, we go back to 80 cents.

Wow. You get to decide when and if people can sell their shares! Man that’s a lot of power!

MRM.... talk to me....

It's perfectly possible that they just took a step back and put basically the same stuff from the abstract on a poster, and presented that.

Meaning, just providing trial population/baseline info, and no actual trial "results".

That seems to me to be most consistent with what we heard from the trial investigator.

Anyone who's been harassing Sleven is an idiot. Infantile, nitwit nonsense.

Whatever he decides to share is up to him. Anyone who has a problem with that should get their diaper changed and go to bed.

I absolutely want it! The efforts are appreciated!

It made it to the final program document, where it was listed as Poster LP019

I could not find that poster anywhere online

I certainly couldn’t find anything

That CTAD abstract said they’d release results at the Oct 24-27 conference

I don’t understand— were the results presented in late October?